Umbilical cord blood procalcitonin and C reactive protein concentrations as markers for early diagnosis of very early onset neonatal infection

N Joram, C Boscher, S Denizot, V Loubersac, N Winer, J C Roze, C Gras-Le Guen

Procalcitonin (PCT) and C reactive protein (CRP) concentrations in umbilical cord blood of 197 neonates were measured to evaluate their value as markers of infection. Sixteen of the neonates were infected. The sensitivity, specificity, and negative and positive predictive values were respectively 87.5%, 98.7%, 87.5%, and 98.7% for PCT and 50%, 97%, 67%, and 94% for CRP. Serum PCT in cord blood seems to be a useful and early marker of antenatal infection.

Judgment criteria
The first judgment criterion was the sensitivity, specificity, and positive and negative predictive values, and positive and negative likelihood ratios of PCT, as assessed by a comparison of PCT concentrations in infected neonates with those in the groups of colonised and non-infected non-colonised neonates. The second criterion involved a comparison of PCT and CRP as predictive markers of neonatal infection.

RESULTS
A total of 197 newborn infants (167 with suspected maternofetal infection and 30 in the control group) were included in the study; 161 were full term and 36 were preterm.

Measurement of PCT and CRP
Figure 1 shows PCT and CRP concentrations for neonates with suspected maternofetal infection, irrespective of term. From the PCT results, we chose 0.5 μg/l as the cut-off point that offered the best sensitivity without significantly decreasing specificity. For CRP, according to the receiver operating characteristic curve, we chose a cut-off point of 5 mg/l, which is lower than the threshold of 10 mg/l, evident in neonatological literature, for postnatal measurements. Only two of the 16 infected newborns had a negative PCT concentration, lower than 0.5 μg/l, and eight of the 16 had a CRP concentration lower than 5 mg/l. On the other hand, only two non-infected neonates had a PCT concentration higher than 0.5 μg/l, four of which had a CRP concentration higher than 5 mg/l. The results were similar in the groups of preterm and full term neonates.

STUDY DESIGN
Patients
We conducted a prospective study from November 2003 to April 2004 in all children born with a suspected maternofetal infection. Three groups were defined according to clinical, biological, and bacterial criteria: infected, colonised, and non-infected non-colonised. Infected neonates had clinical and postnatal biological signs of sepsis, and a positive central (blood or cerebrospinal fluid) or peripheral bacteriological sample. Colonised neonates had a positive gastric sample, without any clinical or biological sign of sepsis. Non-infected non-colonised neonates had no sign of infection and a negative gastric sample. We also studied a group of newborns without any risk factors, which constituted a control group.

Measurements
We measured PCT concentration in umbilical cord blood samples using an immuno-chromatographic semiquantitative test (PCT-Q; Brahms, Hennigsdorf, Germany) and C reactive protein (CRP) concentration using an immunoreactive quantitative method. We also measured PCT in maternal blood to evaluate its relevance in the diagnosis of chorioamnionitis.

Abbreviations: CRP, C reactive protein; PCT, procalcitonin
**DISCUSSION**

PCT measured in umbilical cord blood appears to be a sensitive and specific marker of antenatal infection, with high positive and negative predictive values. It also presents good positive and negative likelihood ratios, and appears to be more reliable than CRP. Focusing on PCT concentrations in umbilical cord blood before the physiological increase or an eventual respiratory or haemodynamic failure makes interpretation of the diagnostic value of PCT concentration easier. On the other hand, the limitation of such an early PCT measurement is that it does not allow the detection of “late” materno-fetal infection related to perpartum or postpartum events.

In clinical practice, PCT measurement in umbilical cord blood should be useful for the early detection of infected neonates, and its good negative predictive value should result in a reduction in the number of patients treated unnecessarily. In particular, PCT measurement should allow the clinician to distinguish infections from simple colonisations. Interestingly, PCT seems to be present in full term and preterm neonates. This reduction in antibiotic prescriptions would represent a direct advantage for neonates, because of the potential toxicity of antibiotics, and an indirect ecological advantage, by reducing antibiotic selection pressure. Although the specificity and negative predictive value for PCT in this study were correct and precisely evaluated with a confidence interval of 1%, the number of infected patients was too small to provide definitive sensitivity and positive predictive value. Although these rapid tests look promising, our results, obtained in a relatively small number of neonates, should be confirmed by a properly designed trial to confirm that PCT is a useful tool for diagnosing sepsis in newborn infants.

**Figure 2** A nomogram of Bayes for applying positive and negative likelihood ratios calculated for selected ranges of values of procalcitonin (PCT) and C reactive protein (CRP). This nomogram compares a pre-test likelihood of being infected with a post-test likelihood. Pre-test probability was 10%, which corresponds to the incidence of this pathology in the population studied. Thus, by using PCT, the likelihood of being infected increases from 10% to 85% when PCT is positive, and the likelihood of being non-infected decreases from 10% to 1% when PCT is below 0.5 µg/l.

**Figure 1** Procalcitonin (PCT) and C reactive protein (CRP) concentration according to septic status.

---

**Authors’ affiliations**

N Joram, C Boscher, S Denizot, J C Roze, C Gras-Le Guen, Département de Pédiatrie, Hôpital Mère Enfant, Nantes, France

V Loubersac, Laboratoire de Biochimie, Nantes

N Winer, Service de Gynécologie Obstétrique, Hôpital Mère Enfant, Nantes

C G-L Guen, Laboratoire d’Antibiologie, Faculté de Médecine, Nantes

Competing interests: none declared

Correspondence to: Dr Gras-le Guen, Département de Pédiatrie, Hôpital Mère Enfant, Quai Moncousu, Chu Nantes, Nantes 44000, France; christelle.grasleguen@chu-nantes.fr

Accepted 22 July 2005

**REFERENCES**


